c-Kit modifies the inflammatory status of smooth muscle cells

Lei Song ¹, Laisel Martinez ², Zachary M Zigmond ¹, Diana R Hernandez ², Roberta M Lassance-Soares ², Guillermo Selman ², Roberto I Vazquez-Padron

¹ Department of Molecular and Cellular Pharmacology, University of Miami, Miami, FL, United States
² Department of Surgery, University of Miami, Miami, FL, United States

Corresponding Author: Roberto I Vazquez-Padron
Email address: rvazquez@med.miami.edu

Background: c-Kit is a receptor tyrosine kinase present in multiple cell types including vascular smooth muscle cells (SMC). However, little is known about how c-Kit influences SMC biology and vascular pathogenesis. Methods: High-throughput microarray assays and in silico pathway analysis were used to identify differentially expressed genes between primary c-Kit deficient (Kit²/²) and control (Kit¹/¹) SMC. Quantitative real-time RT-PCR and functional assays further confirmed the differences in gene expression and pro-inflammatory pathway regulation between both SMC populations. Results: The microarray analysis revealed elevated NF-κB gene expression secondary to the loss of c-Kit that affects both the canonical and alternative NF-κB pathways. Upon stimulation with an oxidized phospholipid as pro-inflammatory agent, c-Kit deficient SMC displayed enhanced NF-κB transcriptional activity, higher phosphorylated/total p65 ratio, and increased protein expression of NF-κB regulated pro-inflammatory mediators with respect to cells from control mice. The pro-inflammatory phenotype of mutant cells was ameliorated after restoring c-Kit activity using lentiviral transduction. Functional assays further demonstrated that c-Kit suppresses NF-κB activity in SMC in a TGFβ-activated kinase 1 (TAK1) and Nemo-like kinase (NLK) dependent manner. Discussion: Our study suggests a novel mechanism by which c-Kit suppresses NF-κB regulated pathways in SMC to prevent their pro-inflammatory transformation.
c-Kit Modifies the Inflammatory Status of Smooth Muscle Cells

Lei Song\textsuperscript{a}, Laisel Martinez\textsuperscript{b}, Zachary M. Zigmond\textsuperscript{a}, Diana R. Hernandez\textsuperscript{b}, Roberta M. Lassance-Soares\textsuperscript{b}, Guillermo Selman\textsuperscript{b}, and Roberto I. Vazquez-Padron\textsuperscript{b,*}

\textsuperscript{a} Molecular and Cellular Pharmacology Department, Leonard M. Miller School of Medicine, University of Miami, Miami, FL 33136

\textsuperscript{b} DeWitt Daughtry Family Department of Surgery, Division of Vascular Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL 33136

* Corresponding Author:

Roberto I. Vazquez-Padron, PhD

1600 NW 10th Ave, RMSB 1048

Miami, FL 33136, United States

Tel: (305) 243-1154

Fax: (305) 243-3134

Email: RVazquez@med.miami.edu
ABSTRACT

Background: c-Kit is a receptor tyrosine kinase present in multiple cell types including vascular smooth muscle cells (SMC). However, little is known about how c-Kit influences SMC biology and vascular pathogenesis. Methods: High-throughput microarray assays and in silico pathway analysis were used to identify differentially expressed genes between primary c-Kit deficient (Kit<sup>W/W-v</sup>) and control (Kit<sup>+/+</sup>) SMC. Quantitative real-time RT-PCR and functional assays further confirmed the differences in gene expression and pro-inflammatory pathway regulation between both SMC populations. Results: The microarray analysis revealed elevated NF-κB gene expression secondary to the loss of c-Kit that affects both the canonical and alternative NF-κB pathways. Upon stimulation with an oxidized phospholipid as pro-inflammatory agent, c-Kit deficient SMC displayed enhanced NF-κB transcriptional activity, higher phosphorylated/total p65 ratio, and increased protein expression of NF-κB regulated pro-inflammatory mediators with respect to cells from control mice. The pro-inflammatory phenotype of mutant cells was ameliorated after restoring c-Kit activity using lentiviral transduction. Functional assays further demonstrated that c-Kit suppresses NF-κB activity in SMC in a TGFβ-activated kinase 1 (TAK1) and Nemo-like kinase (NLK) dependent manner. Discussion: Our study suggests a novel mechanism by which c-Kit suppresses NF-κB regulated pathways in SMC to prevent their pro-inflammatory transformation.
INTRODUCTION

The c-Kit receptor tyrosine kinase is a proto-oncogene and stem cell marker that has been recently implicated in vascular pathogenesis. Widely recognized for its proliferative and anti-apoptotic role in hematopoietic stem and progenitor cells (Bernstein et al. 1991), c-Kit signaling is now known to increase endothelial permeability (Kim et al. 2014; Im et al. 2016), and regulate the phenotype of smooth muscle cells (SMC) in the vasculature (Wang et al. 2007; Davis et al. 2009). On one hand, animal models indicate that c-Kit activation by its ligand the stem cell factor (SCF) plays an important role in the development of both arterial and venous intimal hyperplasia (IH) (Hollenbeck et al. 2004; Wang et al. 2006; Wang et al. 2007; Skartsis et al. 2014). On the other hand, c-Kit expression preserves the SMC contractile phenotype (Davis et al. 2009), and protects arteries from excessive atherosclerosis (Song et al. 2016). Therefore, whether c-Kit is beneficial or detrimental for the vasculature is still a matter of debate and warrants further investigations.

Expression of c-Kit and SCF in vascular myofibroblasts and SMC seems to be tightly regulated by a variety of physiological and pathological triggers. c-Kit positive SMC populate the intima of arteries and veins after vascular injury in models of angioplasty and vein grafting (Hollenbeck et al. 2004; Wang et al. 2006; Wang et al. 2007). Temporal upregulation of both c-Kit and SCF are reported after injury in these models (Hollenbeck et al. 2004; Wang et al. 2006; Wang et al. 2007), where c-Kit dependent induction of the Akt-Bcl-2 cascade is thought to mediate the anti-apoptotic and migratory SMC phenotype responsible for IH (Wang et al. 2007). The formation of venous IH in arteriovenous fistulas (AVF) also occurs secondary to the activation of c-Kit expressing adventitial progenitors and migration of c-Kit positive myofibroblasts to the intima (Skartsis et al. 2014). Both animal and human AVF demonstrate
higher numbers of c-Kit expressing SMC after surgery compared to preoperative veins, along with a transitional increase in SCF levels in animal models after AVF creation (Skartsis et al. 2014).

A small population of c-Kit expressing myofibroblasts/SMC was also found in pulmonary arteries of patients with idiopathic pulmonary arterial hypertension but not in healthy controls (Montani et al. 2011). In line with this evidence, both SCF and c-Kit were upregulated in pulmonary arterioles of experimental animals with pulmonary hypertension, where c-Kit colocalized with cells in the endothelium, media and adventitia (Young et al. 2016). In the latter model, SCF/c-Kit signaling promotes pathological remodeling and pulmonary vascular cell proliferation after hypoxic stimulation via activation of the ERK1/2 pathway (Young et al. 2016). Paradoxically, the presence of c-Kit in human primary pulmonary artery SMC upregulates the transcription factor myocardin and preserves the contractile SMC phenotype (Davis et al. 2009), suggesting a protective role of c-Kit under certain vascular conditions.

Along with the upregulation of c-Kit, the above evidence indicates that SCF is expressed and released in the vasculature in response to different insults (Miyamoto et al. 1997; Hollenbeck et al. 2004; Wang et al. 2007). Vascular SCF exists in both membrane-bound and soluble forms, thus its ability to promote cell recruitment and elicit autocrine and paracrine responses, as well as cell-to-cell stimulation (Hollenbeck et al. 2004; Lennartsson and Ronnstrand 2012; Skartsis et al. 2014). The soluble form of SCF is generated by alternative splicing or released through the proteolytic action of matrix metallopeptidase 9 (MMP-9) (Hollenbeck et al. 2004; Bengatta et al. 2009; Lennartsson and Ronnstrand 2012; Klein et al. 2015). This latter enzyme is also upregulated in vascular remodeling processes, thereby perpetuating the local effects of the SCF/c-Kit pathway (Hollenbeck et al. 2004; Skartsis et al. 2014). Interestingly, the soluble and
membrane-bound SCF isoforms seem to have different effects on c-Kit activation (Miyazawa et al. 1995). The former causes rapid and transient stimulation and autophosphorylation of the receptor as well as fast degradation, whereas the latter leads to sustained activation (Miyazawa et al. 1995). This observation suggests that cell-to-cell interactions between SCF and c-Kit expressing SMC have the potential to significantly modify their respective phenotypes and nearby microenvironment. The concomitant expression of SCF and c-Kit in various cell types (Lennartsson and Ronnstrand 2006; Zakiryanova et al. 2014), including myofibroblasts/SMC (Hollenbeck et al. 2004; Wang et al. 2007; Skartsis et al. 2014), also implies the presence of an autocrine loop for the activation of this receptor. Unfortunately, the available data on the role of c-Kit in vascular remodeling processes is still scarce, and more information is particularly needed on the c-Kit mediated pathways that regulate the SMC phenotypic transformation (Wang et al. 2007).

In this work, we used high-throughput microarray analyses to identify differentially expressed genes as a result of c-Kit loss of function in arterial SMC isolated from mutant and littermate control mice. We combined \textit{in silico} pathway analyses and confirmatory assays to further investigate the gene expression profiles of stimulated SMC under both experimental conditions. We showed increased NF-κB activation in c-Kit deficient SMC compared to their wild type counterparts. Furthermore, we demonstrated that these changes were associated with a heightened state of vascular inflammation, as indicated by the elevated protein expression of pro-inflammatory mediators in c-Kit deficient SMC. Outcomes from this study challenge the existing belief that vascular c-Kit expression is pathological and suggest instead a beneficial contribution of this signaling axis for the preservation of SMC’s anti-inflammatory status under adverse conditions.
MATERIALS AND METHODS

Smooth Muscle Cell Isolation and Culture

Primary aortic SMC were isolated from c-Kit deficient (Kit<sup>W/W-v</sup>) mice and control littermate mice (Kit<sup>+/+</sup>) (Stock #100410, The Jackson Laboratories, Bar Harbor, ME) (Bernstein et al. 1990) using the explant technique (Metz et al. 2012) with minor modifications. Briefly, mouse aortas were digested with collagenase type II (5 mg/mL, Worthington, Lakewood, NJ) at 37°C for 1 hour, after which they were transferred to 10% FBS and cut with a scalpel into small pieces. Individual SMC migrate out of the explants within 1 week of culture. Cells were maintained in DMEM-F12-FBS (5:3:2; Thermo Fisher Scientific, Waltham, MA) supplemented with 100 μg/ml penicillin, 100 μg/ml streptomycin, 0.1 mM glutamine, 10 mM sodium pyruvate, and 0.75% sodium bicarbonate (Metz et al. 2012). Primary cells were maintained at ~90% confluency and used within three passages to avoid fibroblast-like phenotypic switch. All animal procedures were performed according to the National Institutes of Health guidelines (Guide for the Care and Use of Laboratory Animals) and approved by the University of Miami Miller School of Medicine Institutional Animal Care and Use Committee (protocol 15-114).

RNA Microarray and Pathway Analysis

Total RNA was isolated from Kit<sup>+/+</sup> and Kit<sup>W/W-v</sup> SMC using the Quick-RNA MiniPrep kit (Zymo Research, Irvine, CA). RNA quality was validated in the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) before being sent to Ocean Ridge Biosciences (Palm Beach Gardens, FL) for Mouse MI-Ready Gene Expression Microarray analysis. Once in Ocean Ridge Biosciences, RNA processing included a 30-minute digestion with RNase-free DNase I (Epicentre, Madison, WI) at 37°C followed by purification using the AgenCourt RNAClean XP
bead method (Beckman Coulter, Indianapolis, IN). Biotin-labeled complementary RNA (cRNA) was prepared from 2 µg per sample of re-purified RNA by the method of Van Gelder et al. (Van Gelder’s Multi-gene expression profile - US Patent 7049102). Eighteen micrograms of biotinylated cRNA per sample were fragmented, diluted in formamide-containing hybridization buffer, and loaded onto the surface of the Mouse MI-Ready microarray slides enclosed in custom hybridization chambers. The slides were hybridized for 16-18 hours under constant rotation in a Model 400 hybridization oven (Scigene, Sunnyvale, CA). After hybridization, the microarray slides were washed under stringent conditions, stained with Streptavidin-Alexa-647 (Life Technologies, Waltham, MA), and scanned using an Axon GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA). Probe intensities were calculated for each feature on each microarray by subtracting the median local background from the median local foreground for each probe. Data for all manufacturer-flagged probes and visually flagged probes impacting >25% of samples were removed. Data for visually flagged probes impacting < 25% of samples were replaced with the sample average for the probe. Probe intensities were transformed by taking the base 2 logarithm of each value. Array-specific detection thresholds (T) were calculated by adding 3 times the standard deviation of the median local background and the mean negative control probe signal. Probe intensity and T were normalized by subtracting the 70th percentile of the mouse probe intensities and adding back the mean of the 70th percentile across all samples as a scaling factor. The data were filtered to select for mouse probes showing signal above the normalized T in at least 25% of the samples; data for control sequences and other non-mouse probes were removed. Mouse probe sequences were annotated using a BLAST analysis of the Ensembl Mouse cDNA database version 84 (2016). Gene expression differences between Kit\(^{+/+}\) and Kit\(^{W/W-v}\) SMC were considered statistically significant if p<0.05 by \(t\)-test.
For pathway analysis, genes with statistically significant expression differences in microarray analysis were imported into the Ingenuity Pathway Analysis software (www.ingenuity.com; Ingenuity Systems, Redwood City, CA). The Core Analysis was used to identify the canonical pathways associated with the differentially expressed genes. Pathway overlap and p-value calculations were performed using the reference gene set in the Ingenuity Knowledge Base, where only molecular relationships (direct and indirect) that have been experimentally observed were considered. The Molecule Activity Predictor tool was used to estimate activation or inhibition of pathway branches based on the observed gene expression fold changes in Kit\textsuperscript{W/W-v} vs. Kit\textsuperscript{+/+} SMC.

**Quantitative Real-Time PCR (qPCR)**

Relative gene expression of selected mRNA transcripts was evaluated using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA). Total RNA was isolated as described above, and cDNA synthesized with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). Real-time RT-PCR was performed on an ABI Prism 7500 Fast Real-Time PCR System (96-well plate) (Applied Biosystems) using primers/probe sets complementary to the genes of interest (ActB, Mm00607939_m1; Ccl2, Mm00441242_m1; Ikbka, Mm00432529_m1; Ikbkb, Mm01222247_m1; Ikbkg, Mm00494927_m1; Il6, Mm00446190_m1; Kit, Mm00445212_m1; Kitl, Mm00442972_m1; Map3k14, Mm0048444166_m1; Mmp2, Mm00439498_m1; Mmp9, Mm00442991_m1; Nfkb2, Mm00479807_m1; Nfkbia, Mm00477798_m1; Nos2, Mm00440502_m1; Ptgs2, Mm00478374_m1; RelB, Mm00485664-m1; Tnf, Mm00443258_m1). Relative gene expression
was determined using the ΔΔCT method (Livak and Schmittgen 2001) and normalized with
respect to ActB.

**Gene Rescue and Knockdown**

Gene rescue in c-Kit deficient (Kit<sup>W/W<sup>−</sup></sup>−<sup>)</sup> SMC was performed using a lentiviral vector
(pRVPG24). This rescue vector was constructed by inserting a blunted BsrBI-NotI digested
DNA fragment (3.6 Kb), containing the coding region of the mouse Kit cDNA under the murine
phosphoglycerate kinase (PGK) promoter, into the blunted EcoRV-ClaI digested pLenti CMV
PuroDest vector (Addgene Inc., Cambridge, MA). Third generation lentiviral stocks were
produced in HEK-293 cells co-transfected with the lentiviral vector and the packaging and
envelope plasmids psPAX2 and pMD2.G (Addgene Inc.). Transfections were done with the
jetPRIME transfection kit (Polyplus, New York, NY). Infected cells (100 MOI) were selected in
DMEM-F12-FBS (5:3:2; Thermo Fisher Scientific) supplemented with 100 μg/ml penicillin, 100
μg/ml streptomycin, 0.1 mM glutamine, 10 mM sodium pyruvate, 0.75% sodium bicarbonate,
and 10 μg/ml puromycin (Sigma, St Louis, MO).

Knockdown of TAK1 or NLK in c-Kit wild type (Kit<sup>+/+</sup>) SMC was performed using
pooled lentiviral particles carrying different target siRNAs (Supplementary Table 1; Applied
Biological Materials, Richmond, Canada). An anti-GFP siRNA was used as control. Transduced
cells were puromycin-selected as described above. All gene modifications were confirmed by
analytical flow cytometry or Western blot (WB).
Flow Cytometry Analysis

c-Kit surface expression was evaluated by flow cytometry in SMC stained with an anti-
CD117 antibody (CD117-PE, Cat# 130-091730, Miltenyi Biotec, San Diego, CA). Analytical
flow cytometry was performed on a BD FACS Canto II (BD Biosciences, San Jose, CA) using
the BD FACSDiva software (Becton Dickinson, Franklin Lakes, NJ). Data were analyzed using
the FlowJo software (Ashland, OR).

Western Blot and Immunoprecipitation (IP)

Whole cell protein lysates were prepared in RIPA buffer supplemented with 200 mM
phenylmethylsulfonyl fluoride (PMSF), 100mM sodium orthovanadate (Santa Cruz
Biotechnology, Dallas, TX), and a complete protease inhibitor cocktail (Roche Life Science,
Indianapolis, IN). Lysate concentration was determined using a commercial Bradford’s protein
assay kit (BioRad, Hercules, CA). For WB analysis, ~50 µg of sample was loaded into a
NuPAGE 4-12% Bis-Tris SDS-polyacrylamide gel (Thermo Fisher Scientific) and subsequently
transferred to a PVDF membrane (GE Healthcare, Marlborough, MA). Specific proteins were
detected using antibodies against c-Kit (1:1000, Cat# sc-1494, Santa Cruz Biotechnology), MCP-
1, MMP-2, TAK1 (1:500, Cat# sc-1785, sc-1839, and sc-6838, Santa Cruz Biotechnology), NLK
(1:1000, Cat# ab26050, Abcam, San Francisco, CA), Src (1:500, Cat# 2108S, Cell Signaling
Technology, Danvers, MA), and β-Actin (1:5000, Cat# A5316, Sigma). Bound antibodies were
detected after sequentially incubating the membranes with HRP-conjugated secondary
antibodies. The Amersham ECL Western Blotting Detection Reagent (GE Healthcare) or
SuperSignal West Femto Maximum Sensitivity Substrate Reagent (Thermo Fisher Scientific)
were used for signal detection. Images were analyzed using ImageJ Pro 5.0.
For co-IP, ~200 µg of protein lysate was incubated at 4°C for 4 hours with 1 µg of anti- c-Kit (Cat# A4502, Dako, Santa Clara, CA) or TAK1 antibodies and 20 µl of Protein A/G PLUS-Agarose microbeads (Santa Cruz Biotechnologies). Microbeads were washed with cold RIPA buffer before WB analysis for c-Kit, TAK1, or NLK as indicated above.

NF-κB Promoter Activity

Primary SMC were transfected with a commercial mix of NF-κB Luc-reporter plasmids (Qiagen, Germantown, MD) using the Axama Basic Nucleofector Primary Smooth Muscle Cells electroporation kit (Cat# VPI-1004, Lonza, Walkersville, MD). Transfected cells were incubated with 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC; Avanti Polar Lipids, Alabaster, AL) for 24 hours in serum-free medium as previously described (Pidkovka et al. 2007) before lysis using the Passive Lysis Buffer (Promega, Madison, WI). NF-κB promoter activity was determined using the Dual-Luciferase Reporter Assay System (Cat# E1910, Promega) in a Turner Biosystems Luminometer model Glomax 20/20 (Mountain View, CA), and normalized to the Renilla luciferase activity of the kit’s internal control. Promoter activity was expressed as folds of control activity.

Enzyme-Linked Immunosorbent Assay (ELISA)

The levels of cellular NF-κB p65 and phosphorylated protein (p-p65) were measured in SMC treated with POVPC as described above. Cells were lysed using the 1X Cell Extraction Buffer PTR provided in the ELISA kit (Abcam, Cambridge, MA). The ELISA was performed using the NF-κB p65 (pS536 + Total) SimpleStep Kit (Abcam) following the manufacturer’s
Protocol. Protein levels were measured using an endpoint reading at OD 455 nm in an Ultramark Microplate Reader (BioRad).

Statistics

Results are presented as mean ± standard deviation. A two-tailed student t-test was used to compare the difference between two groups, and one-way ANOVA followed by a Newman-Keuls test was applied to compare the difference among multiple groups. A p value <0.05 was considered significant.

RESULTS

Different gene expression profiles in c-Kit positive and deficient smooth muscle cells

Considering the reported contribution of c-Kit to vascular remodeling processes (Hollenbeck et al. 2004; Wang et al. 2006; Wang et al. 2007; Skartsis et al. 2014; Young et al. 2016), we sought for differentially expressed genes between primary SMC isolated from c-Kit deficient (Kit\(^{W/W-v}\)) and control littermate (Kit\(^{+/+}\)) mice (n=3 per strain). Out of a total of 34,265 mouse probes queried by microarray, 18,224 yielded a detectable signal above threshold and 1,086 genes were found differentially expressed between SMC from both experimental groups (p<0.05) (Figure 1A-B). Specifically, 564 and 522 transcripts were significantly up- and downregulated, respectively, with the loss of c-Kit activity with respect to control SMC (Figure 1A). No statistically significant differences in expression were detected by microarray in the remaining 17,138 genes.
Table 1 presents selected differentially expressed genes in c-Kit deficient SMC that are relevant for inflammation such as *Ilf2*, *Ifna14*, and *Tnfsf9* (Zhao et al. 2005; Chan et al. 2006; Croft 2009). We also show decreased expression of the anti-inflammatory genes *Foxo1*, *Gdf6*, *Igf1*, *Igf2r*, and *Lpl* (Ziouzenkova et al. 2003; Sukhanov et al. 2007; Savai et al. 2014; Hisamatsu et al. 2016). Lipoprotein lipase (*Lpl*), for example, is 14-fold lower in c-Kit deficient cells than in those isolated from littermate controls. Additional changes in c-Kit deficient SMC are associated with a downregulation of the contractile SMC phenotype (increased *Tnfaip3* and reduced *Sirt1*) (Damrauer et al. 2010; Huang et al. 2015) and higher susceptibility to calcification (decreased *Foxo1* and *Pth1r*) (Cheng et al. 2010; Deng et al. 2015). Finally, we found significant expression differences in genes that code for cell adhesion proteins and for receptors and enzymes that regulate vasomotor responses (Table 1).

Confirmatory real-time RT-PCR assays were performed for selected inflammation-related genes that showed a trend by microarray analysis. Tumor necrosis factor (*Tnf*), interleukin 6 (*Il6*), C-C motif chemokine ligand 2 (*Ccl2*), metalloproteinases 2 and 9 (*Mmp2*, *Mmp9*), inducible nitric oxide synthase (*Nos2*), and cyclooxygenase 2 (*Ptgs2*) were significantly upregulated in c-Kit deficient SMC compared to controls (Figure 1C).

**Predicted activation of NF-κB signaling in c-Kit deficient cells by pathway analysis**

*In silico* pathway analysis was used to predict the molecular pathways affected by the loss of c-Kit in SMC. A total of 71 statistically significant pathways were identified (p<0.05) by the software, 42 of which with a biologically relevant function in SMC. These pathways covered cellular processes such as cell survival and apoptosis, inflammation, cell adhesion, nitric oxide signaling, and lipid metabolism (Table 2). Interestingly, 10 independent molecular pathways were associated with NF-κB signaling, and all of them showed either predicted activation of the
entire pathway (5/10; z-scores ranging from 0.258 to 1.265) or of the NF-κB branch (5/10) in c-Kit deficient SMC (Table 2).

**Upregulation of NF-κB pathway genes in c-Kit deficient smooth muscle cells**

The NF-κB pathway plays a fundamental role in SMC differentiation, inflammation, and response to stress signals (Zahradka et al. 2002; Ramana et al. 2004; Mehrhof et al. 2005; Mack 2011). Therefore, we confirmed the upregulation of components of this pathway in c-Kit deficient cells by real-time RT-PCR (Figure 1D). We found significantly higher expression levels of genes that are part of both the canonical (*Ikbka, Ikbkb, Ikbkg, Nfkbia*) and alternative (*Ikbka, Map3k14, Nfkb2, RelB*) NF-κB signaling pathways in Kit\(^{W/W-v}\) vs. Kit\(^{+/+}\) SMC.

**Increased activity of the canonical NF-κB pathway in stimulated c-Kit deficient cells**

Given that the inhibitor of the canonical NF-κB pathway (*Nfkbia*) and the negative regulator *Tnfaip3* are upregulated in c-Kit deficient SMC (Table 1, Figure 1D), we turned to demonstrate the relationship between c-Kit expression and functional activity of the NF-κB signaling pathway. To further validate our findings, we rescued c-Kit expression in Kit\(^{W/W-v}\) SMC by lentiviral transduction (Supplementary Figure 1).

POVPC-stimulated SMC with deficient c-Kit expression showed higher NF-κB transcriptional activity compared to wild type and c-Kit rescued cells as determined by a dual luciferase reporter assay (Figure 2A). Accordingly, a significantly higher ratio of the S536-phosphorylated/total p65 factor was detected in Kit\(^{W/W-v}\) SMC vs. wild type and rescued cells (Figure 2B), demonstrating increased availability of active p65 in c-Kit deficient SMC for nuclear translocation and promoter binding (Lawrence 2009). Finally, we evaluated the protein concentrations of the pro-inflammatory mediators MMP-2 and MCP-1 in POVPC-stimulated
SMC, two factors that are regulated by NF-κB (Lee et al. 2008; Song et al. 2016). In agreement with the enhanced transcriptional activity shown above, the protein expressions of both MMP-2 and MCP-1 were significantly higher in Kit\textsuperscript{W/W-v} SMC compared to wild type and rescued cells (Figure 2C). To control for off-target effects of POVPC stimulation on c-Kit expression, we demonstrated that this treatment did not modify the cellular levels of SCF or the receptor (Supplementary Figure 2).

**c-Kit regulates NF-κB activation through TAK1/NLK in smooth muscle cells**

Previous studies indicate an association between c-Kit, Lyn (a member of the Src family of non-receptor tyrosine kinases), and TAK1 (Drube et al. 2015), a negative regulator of NF-κB signaling (Ajibade et al. 2012). Therefore, we assessed whether this latter factor or its downstream partner NLK (Yasuda et al. 2004; Li et al. 2014) were responsible for the observed inhibition of the NF-κB pathway in c-Kit expressing SMC. We found that the protein expressions of both TAK1 and NLK were reduced or lost in Kit\textsuperscript{W/W-v} SMC compared to wild type or c-Kit rescued cells (Figure 3A). Next, we selectively knocked down TAK1 or NLK in Kit\textsuperscript{+/+} SMC (Figure 3B-C), and showed that this genetic manipulation restored the NF-κB transcriptional activity, phosphorylated/total p65 ratio, and protein expressions of MMP-2 and MCP1 in POVPC-stimulated c-Kit wild type SMC (Figure 3D-F). Lastly, we demonstrated by co-IP a physical interaction between all c-Kit, Src, TAK1, and NLK (Figure 4), further supporting a direct relationship in NF-κB regulation. Altogether, these experiments demonstrate that c-Kit inhibits NF-κB signaling in SMC through the actions of TAK1 and NLK.
DISCUSSION

Vascular SMC are characterized by tremendous phenotypic diversity (Yoshida and Owens 2005). Moreover, their contribution to vascular pathogenesis greatly depends on their phenotype and state of differentiation (Archer 1996; Yoshida and Owens 2005). Expression of the c-Kit receptor in SMC has been associated with various vascular pathologies in both animal models (Wang et al. 2006; Wang et al. 2007; Skartsis et al. 2014; Young et al. 2016) and human samples (Hollenbeck et al. 2004; Skartsis et al. 2014). In contrast, it has also proven protective in models of atherosclerosis (Song et al. 2016). In light of this evidence, there is little information on how c-Kit influences the phenotypes of SMC or the mechanisms by which they contribute to pathology. Our work reveals that the absence of c-Kit modified the expression of approximately 6% of the genes that were detected by microarray in SMC from c-Kit mutant and littermate control mice. Furthermore, we provide evidence that c-Kit suppresses NF-κB signaling in SMC and decreases the production of pro-inflammatory mediators under stimulus.

Using in silico pathway analysis, we first demonstrated that c-Kit signaling influences a wide variety of cellular processes in SMC. Specifically, we found evidence of a pro-synthetic and pro-inflammatory phenotype in SMC secondary to the loss of this receptor. This is particularly evident by the potential dysregulation of lipid metabolism as indicated by a 14-fold decrease in Lpl gene expression. While increased vascular lipoprotein lipase can be pro-atherogenic (Clee et al. 2000), it is also believed to have anti-inflammatory properties both by generating metabolic PPAR agonists and inhibiting NF-κB activity (Ziouzenkova et al. 2003; Kota et al. 2005). c-Kit deficient cells also have decreased expression of the anti-inflammatory and anti-atherogenic factor IGF-1 (Sukhanov et al. 2007) and increased susceptibility to calcification due to the downregulation of the Foxo1 and Pth1r genes (Cheng et al. 2010; Deng et
et al. 2015). It is possible that these changes explain the increased severity of atherosclerosis in c-Kit mutant animals (Song et al. 2016). In addition, c-Kit deficient SMC appear to respond differently to vasomotor stimuli. Their gene expression profile indicates a significantly lower expression of vasoconstrictive G-protein coupled receptors such as the angiotensin II receptor type 1B and the arginine vasopressin receptor 1A. The response to nitric oxide may be also impaired in these cells due to a lower expression of guanylate cyclase 1 soluble subunit beta and cGMP-dependent protein-kinase type I. In the absence of functional experiments, it is not clear what is the biological impact of the above differences in c-Kit deficient SMC compared to their wild type counterparts. However, these observations warrant further investigations.

Interestingly, 24% of the differentially regulated pathways identified were associated with NF-κB signaling. Furthermore, both the in silico analysis and our experimental data demonstrated activation of this pathway in c-Kit deficient SMC with respect to those from littermate controls. NF-κB signaling is critical for the regulation of proliferation, differentiation, stress responses, and inflammatory processes in vascular SMC (Zahradka et al. 2002; Ramana et al. 2004; Mehrhof et al. 2005; Mack 2011). Whether NF-κB activation is associated with increased proliferation or apoptosis in SMC is dependent on the upstream stimuli and the type of vessel (Zahradka et al. 2002; Mehrhof et al. 2005; Ogbozor et al. 2015). A recent study demonstrated that NF-κB activation led to increased proliferation in fibroblasts, while inducing apoptosis and inflammation in SMC (Mehrhof et al. 2005). On the other hand, NF-κB was shown to be an important intracellular mediator of angiotensin II responses, leading to SMC proliferation and migration under these conditions (Zahradka et al. 2002). In terms of cell differentiation, NF-κB is known to repress myocardin activity and cause downregulation of SMC contractile genes (Tang et al. 2008). This molecular interaction has been implicated in the origin
of synthetic SMC under inflammatory processes such as atherosclerosis (Mack 2011).

Interestingly, the reduced expression of Sirt and increased mRNA level of Tnfaip3 in c-Kit deficient cells are independently associated with downregulation of contractile genes in SMC (Damrauer et al. 2010; Huang et al. 2015). These observations are in agreement with the predicted de-differentiated phenotype of c-Kit deficient SMC (Davis et al. 2009) and with the reported atheroprotective role of the c-Kit receptor (Song et al. 2016). TNFAIP3 normally provides a negative regulatory loop for the NF-κB pathway, including the decreased downstream production of the MCP-1 inflammatory mediator (Patel et al. 2006; Giordano et al. 2014).

Downregulation of the Crebbp transcription factor is also thought to reduce NF-κB transcriptional activity (Yang et al. 2010). Nonetheless, neither higher Tnfaip3 expression nor less Crebbp in c-Kit deficient SMC seem to have an appreciable inhibitory effect on NF-κB signaling, as demonstrated by our functional experiments and the increased protein expressions of the MMP-2 and MCP-1 factors.

Typical stimuli for NF-κB activation include cytokines, endotoxins, lipids, and mechanical stress (Maziere et al. 1996; De Martin et al. 2000; Kumar and Boriek 2003). For example, the oxidized phospholipid POVPC has been previously used to induce inflammation in vascular SMC (Pidkovka et al. 2007; Lu et al. 2013) and NF-κB activation (Pegorier et al. 2006; Vladykovskaya et al. 2011; Lu et al. 2013). As predicted by the in silico analysis, c-Kit deficiency in SMC led to higher levels of NF-κB transcriptional activity, phosphorylation of its key subunit p65, and expression of the NF-κB regulated inflammatory mediators MMP-2 and MCP-1 under POVPC challenge. Gene members of the non-canonical NF-κB pathway and other inflammatory mediators were also upregulated in mutant SMC.
The role of c-Kit as a negative regulator of the NF-κB pathway and related inflammation has been previously observed in other cell types and under different stimuli (Jin et al. 2013; Micheva-Viteva et al. 2013). Pharmacological inhibition of c-Kit results in increased activation of NF-κB in HEK293 cells and secretion of TNFα in dendritic cells and the THP-1 monocytic cell line in response to bacterial infection (Micheva-Viteva et al. 2013). Lower expressions of SCF and c-Kit were also associated with increased NF-κB signaling and oxidative stress in gastric smooth muscle (Jin et al. 2013).

Our experiments further revealed that c-Kit reduces NF-κB mediated inflammation via a direct molecular interaction with the NF-κB negative regulators TAK1 and NLK (Yasuda et al. 2004; Ajibade et al. 2012; Li et al. 2014). The physical association between c-Kit, Lyn (a member of the Src family of non-receptor tyrosine kinases), and TAK1 has been previously observed in the HEK293T cell line, where these proteins form a signalosome that interacts with IKKβ, one of the catalytic units of the IκB kinase (IKK) complex (Drube et al. 2015). Nonetheless, the inhibitory activity of TAK1 on the NF-κB signaling pathway appears to be cell-specific, since in some cells it can be activating (Israel 2010; Ajibade et al. 2012). In the inhibitory instances, TAK1 blocks the phosphorylation and inactivates IKK (Ajibade et al. 2012), which in turn is unable to phosphorylate and induce proteosomal degradation of the IκB inhibitors of the NF-κB pathway (Karin 1999; Israel 2010). When active, IκB proteins prevent the nuclear translocation of p65/RelA complexes (Karin 1999; Israel 2010). NLK also functions as an inhibitor of IKK phosphorylation (even in cells where TAK1 acts as an activator) (Li et al. 2014). Therefore, our data indicate that in SMC the roles of TAK1 and NLK may be redundant.

In conclusions, our study demonstrates that c-Kit expression in SMC has an anti-inflammatory role. Our mechanistic studies contradict the existing belief about the noxious effect
of SCF/c-Kit signaling to the vasculature. It is noteworthy to recognize that such idea originated
from descriptive studies and models of post injury IH. The current knowledge describes the
expression of SCF and its receptor c-Kit in endothelial cells and SMC (Hollenbeck et al. 2004;
Matsui et al. 2004; Wang et al. 2007; Skartsis et al. 2014), and suggests a key role for this
signaling pathway in myofibroblast mobilization towards the neointima (Hollenbeck et al. 2004;
Skartsis et al. 2014). Increased survival of SCF-treated SMC through Akt has also been
demonstrated (Wang et al. 2007). In contrast, one recent study revealed that SCF/c-Kit signaling
protects hyperlipidemic ApoE<sup>−/−</sup> mice from excessive atherosclerotic plaque deposition (Song et
al. 2016). This apparent discrepancy may reflect the existing differences between IH (restenosis)
and atherosclerosis in terms of etiology, natural history, culprit lesions, and progenitor cell
contribution to disease progression. Therefore, our results suggests that while c-Kit positive cells
have a detrimental effect on proliferative vascular lesions, their presence may prove protective in
inflammatory conditions such as atherosclerosis. In addition, we propose a novel pathway for
NF-κB regulation downstream of c-Kit activation. This information could be relevant in the
setting of atherosclerosis disease development and complications, and may shed light on new
proliferation control mechanisms to address IH after vascular injury.
FIGURE LEGENDS

Figure 1. Loss of c-Kit function accounts for significant gene expression differences between c-Kit deficient and wild type smooth muscle cells (SMC). A) Venn diagram indicating the numbers of differentially upregulated genes in primary SMC isolated from c-Kit deficient (blue; Kit$^{W/W-v}$) and littermate control mice (red; Kit$^{+/+}$) as determined by microarray analysis. The group of genes in the interception (black area) did not show statistically significant differences by t-test between the two strains (n=3 per group). B) Heat map of differentially expressed genes in primary SMC from c-Kit deficient and littermate control mice. C-D) Relative expression of inflammatory (C) and NF-κB related (D) genes in c-Kit deficient vs. control SMC as determined by real-time RT-PCR. Values are shown as fold change over expression in Kit$^{+/+}$ cells; * p<0.05 and ** p<0.01 using a two-tailed t-test assuming unequal variance, n=3 per group.

Figure 2. Loss of c-Kit function in primary smooth muscle cells (SMC) is associated with increased NF-κB activity. A) NF-κB transcriptional activity in c-Kit deficient (Kit$^{W/W-v}$), control (Kit$^{+/+}$), and c-Kit rescued SMC (Kit$^R$) after 24-hour treatment with POVPC (50 µg/ml), as determined by dual-luciferase reporter assay. Transcriptional activity is represented as the mean ± standard deviation (SD) of the Firefly/Renilla luciferase ratio normalized with respect to the control group (Kit$^{+/+}$) (n=3 independent experiments). B) Phosphorylated (pS536) protein levels of the NF-κB p65 subunit in POVPC-treated c-Kit deficient, control, and c-Kit rescued SMC as determined by ELISA. Values are expressed as the mean ± SD of the p-p65/total p65 ratio normalized with respect to the control group (Kit$^{+/+}$) (n=3 independent experiments). C) Protein expression of the NF-κB related pro-inflammatory mediators MMP-2 and MCP-1 in POVPC-treated c-Kit deficient, control, and c-Kit rescued SMC as determined by Western blot.
Molecular weight markers are shown on the right side of the gel. Protein expression is expressed as the mean ± SD of the MMP-2/β-actin and MCP-1/β-actin signal ratios normalized with respect to the control group (Kit^{+/+}) (n=3 per cell type). * p<0.05 and ** p<0.01 using a one-way ANOVA followed by a Newman-Keuls test.

**Figure 3.** c-Kit inhibits NF-κB activity in smooth muscle cells (SMC) through the actions of TAK1 and NLK. A) Protein expression of the TAK1 and NLK regulatory proteins in c-Kit deficient (Kit^{W/W-v}), control (Kit^{+/+}), and c-Kit rescued SMC (Kit^{R}) as determined by Western blot. Protein expression is expressed as the mean ± standard deviation (SD) of the TAK1/β-actin and NLK/β-actin signal ratios normalized with respect to the control group (Kit^{+/+}) (n=3 per cell type). B-C) Protein expression of TAK1 (B) and NLK (C) in Kit^{+/+} cells transduced with lentivirus-encoded siRNAs of the corresponding targets or GFP control. Protein expression is expressed as the mean ± SD of the TAK1/β-actin and NLK/β-actin signal ratios normalized with respect to the siGFP-treated group (n=3 independent experiments). D) NF-κB transcriptional activity in Kit^{+/+} SMC transduced with lentivirus-encoded siRNAs complementary to TAK1, NLK, or GFP after 24-hour treatment with POVPC (50 µg/ml), as determined by dual-luciferase assay. Transcriptional activity is represented as the mean ± SD of the Firefly/Renilla luciferase ratio normalized with respect to the siGFP-treated group (n=3 independent experiments). E) Phosphorylated (pS536) protein levels of NF-κB p65 in POVPC-treated Kit^{+/+} SMC transduced with lentivirus-encoded siRNAs as determined by ELISA. Values are expressed as the mean ± SD of the p-p65/total p65 ratio normalized with respect to the siGFP-treated group (n=3 independent experiments). F) Protein expression of the pro-inflammatory mediators MMP-2 and MCP-1 in POVPC-treated Kit^{+/+} SMC transduced with lentivirus-encoded siRNAs as determined by Western blot. Protein expression is expressed as the mean ± SD of the MMP-2/β-actin and...
MCP-1/β-actin signal ratios normalized with respect to the siGFP-treated group (n=3 independent experiments). Molecular weight markers are shown on the right side of the gels. * p<0.05 and ** p<0.01 using a one-way ANOVA followed by a Newman-Keuls test.

Figure 4. c-Kit forms a molecular complex with the regulatory proteins TAK1, Src, and NLK in smooth muscle cells (SMC). A) Diagram illustrating the proposed molecular complex between c-Kit, TAK1, Src, and NLK in SMC and their inhibitory function on NF-κB regulated transcriptional activity. B-C) Co-immunoprecipitation experiments in control (Kit^{+/+}) and c-Kit deficient (Kit^{W/W-v}) SMC using anti-c-Kit (B) and anti-TAK1 antibodies (C) to pull down protein complexes. Molecular weight markers are shown on the right side of the gels, while antibodies used to detect eluted proteins are indicated on the left. IP, immunoprecipitation; IB, immunoblot.
REFERENCES

Ajibade, AA, Q Wang, J Cui, J Zou, X Xia, M Wang, Y Tong, W Hui, D Liu, B Su, HY Wang and RF Wang. 2012. Tak1 negatively regulates nf-kappab and p38 map kinase activation in gr-1+cd11b+ neutrophils. *Immunity* 36: 43-54.

Archer, SL. 1996. Diversity of phenotype and function of vascular smooth muscle cells. *J Lab Clin Med* 127: 524-529.

Bengatta, S, C Arnould, E Letavernier, M Monge, HM de Preneuf, Z Werb, P Ronco and B Lelongt. 2009. Mmp9 and scf protect from apoptosis in acute kidney injury. *J Am Soc Nephrol* 20: 787-797.

Bernstein, A, B Chabot, P Dubreuil, A Reith, K Nocka, S Majumder, P Ray and P Besmer. 1990. The mouse w/c-kit locus. *Ciba Found Symp* 148: 158-166; discussion 166-172.

Bernstein, A, L Forrester, AD Reith, P Dubreuil and R Rottapel. 1991. The murine w/c-kit and steel loci and the control of hematopoiesis. *Semin Hematol* 28: 138-142.

Chan, A, DL Newman, AM Shon, DH Schneider, S Kuldanek and C Ober. 2006. Variation in the type i interferon gene cluster on 9p21 influences susceptibility to asthma and atopy. *Genes Immun* 7: 169-178.

Cheng, SL, JS Shao, LR Halstead, K Distelhorst, O Sierra and DA Towler. 2010. Activation of vascular smooth muscle parathyroid hormone receptor inhibits wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. *Circ Res* 107: 271-282.

Clee, SM, N Bissada, F Miao, L Miao, AD Marais, HE Henderson, P Steures, J McManus, B McManus, RC LeBoeuf, JJ Kastelein and MR Hayden. 2000. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. *J Lipid Res* 41: 521-531.

Croft, M. 2009. The role of tnf superfamily members in t-cell function and diseases. *Nat Rev Immunol* 9: 271-285.

De Martin, R, M Hoeth, R Hofer-Warbinek and JA Schmid. 2000. The transcription factor nf-kappa b and the regulation of vascular cell function. *Arterioscler Thromb Vasc Biol* 20: E83-88.

Deng, L, L Huang, Y Sun, JM Heath, H Wu and Y Chen. 2015. Inhibition of foxo1/3 promotes vascular calcification. *Arterioscler Thromb Vasc Biol* 35: 175-183.

Drube, S, F Weber, C Gopfert, R Loschinski, M Rothe, F Boelke, MA Diamanti, T Lohn, J Ruth, D Schutz, N Hafner, FR Greten, R Stumm, K Hartmann, OH Kramer, A Dudeck and T Kamradt. 2015. Tak1 and ikk2, novel mediators of scf-induced signaling and potential targets for c-kit-driven diseases. *Oncotarget* 6: 28833-28850.

Giordano, M, R Roncagalli, P Bourdely, L Chasson, M Buferne, S Yamasaki, R Beyaert, G van Loo, N Auphan-Anezin, AM Schmitt-Verhulst and G Verdeil. 2014. The tumor necrosis factor alpha-induced protein 3 (tnfaip3, a20) imposes a brake on antitumor activity of cd8 t cells. *Proc Natl Acad Sci U S A* 111: 11115-11120.
Hisamatsu, D, M Ohno-Oishi, S Nakamura, Y Mabuchi and H Naka-Kaneda. 2016. Growth differentiation factor 6 derived from mesenchymal stem/stromal cells reduces age-related functional deterioration in multiple tissues. *Aging (Albany NY)* 8: 1259-1275.

Hollenbeck, ST, K Sakakibara, PL Faries, B Workhu, B Liu and KC Kent. 2004. Stem cell factor and c-kit are expressed by and may affect vascular smcs through an autocrine pathway. *J Surg Res* 120: 288-294.

Huang, K, ZQ Yan, D Zhao, SG Chen, LZ Gao, P Zhang, BR Shen, HC Han, YX Qi and ZL Jiang. 2015. Sirt1 and foxo mediate contractile differentiation of vascular smooth muscle cells under cyclic stretch. *Cell Physiol Biochem* 37: 1817-1829.

Im, JE, SH Song and W Suh. 2016. Src tyrosine kinase regulates the stem cell factor-induced breakdown of the blood-retinal barrier. *Mol Vis* 22: 1213-1220.

Israel, A. 2010. The ikk complex, a central regulator of nf-kappab activation. *Cold Spring Harb Perspect Biol* 2: a000158.

Jin, QH, HX Shen, H Wang, QY Shou and Q Liu. 2013. Curcumin improves expression of scf/c-kit through attenuating oxidative stress and nf-kappab activation in gastric tissues of diabetic gastroparesis rats. *Diabetol Metab Syndr* 5: 12.

Karin, M. 1999. How nf-kappab is activated: The role of the ikkappab kinase (ikk) complex. *Oncogene* 18: 6867-6874.

Kim, JY, JS Choi, SH Song, JE Im, JM Kim, K Kim, S Kwon, HK Shin, CK Joo, BH Lee and W Suh. 2014. Stem cell factor is a potent endothelial permeability factor. *Arterioscler Thromb Vasc Biol* 34: 1459-1467.

Klein, G, O Schmal and WK Aicher. 2015. Matrix metalloproteinases in stem cell mobilization. *Matrix Biol* 44-46: 175-183.

Kota, RS, CV Ramana, FA Tenorio, RI Enelow and JC Rutledge. 2005. Differential effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-gamma-mediated gene expression in human endothelial cells. *J Biol Chem* 280: 31076-31084.

Kumar, A and AM Boriek. 2003. Mechanical stress activates the nuclear factor-kappab pathway in skeletal muscle fibers: A possible role in duchenne muscular dystrophy. *FASEB J* 17: 386-396.

Lawrence, T. 2009. The nuclear factor nf-kappab pathway in inflammation. *Cold Spring Harb Perspect Biol* 1: a001651.

Lee, SJ, KW Seo, MR Yun, SS Bae, WS Lee, KW Hong and CD Kim. 2008. 4-hydroxynonenal enhances mmp-2 production in vascular smooth muscle cells via mitochondrial ros-mediated activation of the akt/nf-kappab signaling pathways. *Free Radic Biol Med* 45: 1487-1492.

Lennartsson, J and L Ronnstrand. 2006. The stem cell factor receptor/c-kit as a drug target in cancer. *Curr Cancer Drug Targets* 6: 65-75.

Lennartsson, J and L Ronnstrand. 2012. Stem cell factor receptor/c-kit: From basic science to clinical implications. *Physiol Rev* 92: 1619-1649.

Li, SZ, HH Zhang, JB Liang, Y Song, BX Jin, NN Xing, GC Fan, RL Du and XD Zhang. 2014. Nemo-like kinase (nlk) negatively regulates nf-kappa b activity through disrupting the interaction of tak1 with ikkbeta. *Biochim Biophys Acta* 1843: 1365-1372.

Livak, KJ and TD Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method. *Methods* 25: 402-408.
MK Jain. 2013. Kruppel-like factor 15 is critical for vascular inflammation. *J Clin Invest* 123: 4232-4241.

Mack, CP. 2011. Signaling mechanisms that regulate smooth muscle cell differentiation. *Arterioscler Thromb Vasc Biol* 31: 1495-1505.

Matsui, J, T Wakabayashi, M Asada, K Yoshimatsu and M Okada. 2004. Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. *J Biol Chem* 279: 18600-18607.

Maziere, C, M Auclair, M Djavaheri-Mergny, L Packer and JC Maziere. 1996. Oxidized low density lipoprotein induces activation of the transcription factor nf kappa b in fibroblasts, endothelial and smooth muscle cells. *Biochem Mol Biol Int* 39: 1201-1207.

Mehrhof, FB, R Schmidt-Ullrich, R Dietz and C Scheidereit. 2005. Regulation of vascular smooth muscle cell proliferation: Role of nf-kappab revisited. *Circ Res* 96: 958-964.

Metz, RP, JL Patterson and E Wilson. 2012. Vascular smooth muscle cells: Isolation, culture, and characterization. *Methods Mol Biol* 843: 169-176.

Micheva-Viteva, SN, Y Shou, KL Nowak-Lovato, KD Rector and E Hong-Geller. 2013. C-kit signaling is targeted by pathogenic yersinia to suppress the host immune response. *BMC Microbiol* 13: 249.

Miyamoto, T, Y Sasaguri, T Sasaguri, S Azakami, H Yasukawa, S Kato, N Arima, K Sugama and M Morimatsu. 1997. Expression of stem cell factor in human aortic endothelial and smooth muscle cells. *Atherosclerosis* 129: 207-213.

Miyazawa, K, DA Williams, A Gotoh, J Nishimaki, HE Broxmeyer and K Toyama. 1995. Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. *Blood* 85: 641-649.

Montani, D, F Perros, N Gambaryan, B Girerd, P Dorfmuller, LC Price, A Huertas, H Hammad, B Lambrecht, G Simonneau, JM Launay, S Cohen-Kaminsky and M Humbert. 2011. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 184: 116-123.

Ogbozor, UD, M Opene, LS Renteria, S McBride and BO Ibe. 2015. Mechanism by which nuclear factor-kappa beta (nf-kb) regulates ovine fetal pulmonary vascular smooth muscle cell proliferation. *Mol Genet Metab Rep* 4: 11-18.

Patel, VI, S Daniel, CR Longo, GV Shrikhande, ST Scali, E Czismadia, CM Groft, T Shukri, C Motley-Dore, HE Ramsey, MD Fisher, ST Grey, MB Arvelo and C Ferran. 2006. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. *FASEB J* 20: 1418-1430.

Pegorier, S, D Stengel, H Durand, M Croset and E Ninio. 2006. Oxidized phospholipid: Povpc binds to platelet-activating-factor receptor on human macrophages. Implications in atherosclerosis. *Atherosclerosis* 188: 433-443.

Pikkovka, NA, OA Cherepanova, T Yoshida, MR Alexander, RA Deaton, JA Thomas, N Leitinger and GK Owens. 2007. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. *Circ Res* 101: 792-801.

Ramana, KV, B Friedrich, S Srivastava, A Bhatnagar and SK Srivastava. 2004. Activation of nuclear factor-kappab by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. *Diabetes* 53: 2910-2920.

Savai, R, HM Al-Tamari, D Sedding, B Kojonazarov, C Muecke, R Teske, MR Capecchi, N Weissmann, F Grimminger, W Seeger, RT Schermuly and SS Pullamsetti. 2014. Pro-
proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. *Nat Med* 20: 1289-1300.

Skartsis, N, L Martinez, JC Duque, M Tabbara, OC Velazquez, A Asif, F Andreopoulos, LH Salman and RI Vazquez-Padron. 2014. C-kit signaling determines neointimal hyperplasia in arteriogenous fistulae. *Am J Physiol Renal Physiol* 307: F1095-1104.

Song, L, C Kang, Y Sun, W Huang, W Liu and Z Qian. 2016. Crocetin inhibits lipopolysaccharide-induced inflammatory response in human umbilical vein endothelial cells. *Cell Physiol Biochem* 40: 443-452.

Song, L, G Selman, N Santos, L Martinez, RMlassance-Soares, K Webster and RI Vazquez-Padron. 2016. C-kit expression in vascular smooth muscle cells protects mice against excessive atherosclerosis. *Circulation* 134: A14889.

Sukhanov, S, Y Higashi, SY Shai, C Vaughn, J Mohler, Y Li, YH Song, J Titterington and P Delafontaine. 2007. Igf-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in apoE-deficient mice. *Arterioscler Thromb Vasc Biol* 27: 2684-2690.

Tang, RH, XL Zheng, TE Callis, WE Stansfield, J He, AS Baldwin, DZ Wang and CH Selzman. 2008. Myocardin inhibits cellular proliferation by inhibiting NF-kappab(p65)-dependent cell cycle progression. *Proc Natl Acad Sci U S A* 105: 3362-3367.

Vladykovskaya, E, E Ozhegov, JD Hoetker, Z Xie, Y Ahmed, J Suttle, S Srivastava, A Bhatnagar and OA Barski. 2011. Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids. *J Lipid Res* 52: 2209-2225.

Wang, CH, N Anderson, SH Li, PE Szmitko, WJ Cherng, PW Fedak, S Fazel, RK Li, TM Yau, RD Weisel, WL Stanford and S Verma. 2006. Stem cell factor deficiency is vasculoprotective: Unraveling a new therapeutic potential of imatinib mesylate. *Circ Res* 99: 617-625.

Wang, CH, S Verma, IC Hsieh, A Hung, TT Cheng, SY Wang, YC Liu, WL Stanford, RD Weisel, RK Li and WJ Cherng. 2007. Stem cell factor attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after vascular injury. *Arterioscler Thromb Vasc Biol* 27: 540-547.

Yang, J, H Jiang, SS Chen, J Chen, SK Xu, WQ Li and JC Wang. 2010. Cbp knockdown inhibits angiotensin ii-induced vascular smooth muscle cells proliferation through downregulating nf-kb transcriptional activity. *Mol Cell Biochem* 340: 55-62.

Yasuda, J, H Yokoo, T Yamada, I Kitabayashi, T Sekiya and H Ichikawa. 2004. Nemo-like kinase suppresses a wide range of transcription factors, including nuclear factor-kappab. *Cancer Sci* 95: 52-57.

Yoshida, T and GK Owens. 2005. Molecular determinants of vascular smooth muscle cell diversity. *Circ Res* 96: 280-291.

Young, KC, E Torres, D Hehre, S Wu, C Suguihara and JM Hare. 2016. Antagonism of stem cell factor/c-kit signaling attenuates neonatal chronic hypoxia-induced pulmonary vascular remodeling. *Pediatr Res* 79: 637-646.

Zahradka, P, JP Werner, S Buhay, B Litchie, G Helwer and S Thomas. 2002. Nf-kappab activation is essential for angiotensin ii-dependent proliferation and migration of vascular smooth muscle cells. *J Mol Cell Cardiol* 34: 1609-1621.

Zakiryanova, G, O Karpova, O Khamdiyeva, D Kopytina, N Urazalieva, E Kustova and Z Biyasheva. 2014. C-kit/scf autocrine loop in human nk cells (ccr5p.254). *J Immunol* 192: 181.188.
Zhao, G, L Shi, D Qiu, H Hu and PN Kao. 2005. Nf45/ilf2 tissue expression, promoter analysis, and interleukin-2 transactivating function. *Exp Cell Res* 305: 312-323.

Ziouzenkova, O, S Perrey, L Asatryan, J Hwang, KL MacNaul, DE Moller, DJ Rader, A Sevanian, R Zechner, G Hoefler and J Plutzky. 2003. Lipolysis of triglyceride-rich lipoproteins generates ppar ligands: Evidence for an antiinflammatory role for lipoprotein lipase. *Proc Natl Acad Sci U S A* 100: 2730-2735.
Table 1. Selected list of differentially expressed genes in c-Kit deficient vs. wild type smooth muscle cells
| Gene Symbol | Gene Product                                      | Fold Change | P-Value |
|-------------|--------------------------------------------------|-------------|---------|
| Crebbp      | CREB binding protein                             | -1.18       | 0.010   |
| Foxo1       | Forkhead box O1                                  | -2.05       | 0.007   |
| Ilf2        | Interleukin enhancer binding factor 2            | 1.38        | 0.034   |
| Irf3        | Interferon regulatory factor 3                   | -1.14       | 0.029   |
| Nfatc1      | Nuclear factor of activated T-cells 1            | -1.36       | 0.040   |
| Nfatc2      | Nuclear factor of activated T-cells 2            | 2.01        | 0.033   |
| Nfatc4      | Nuclear factor of activated T-cells 4            | -2.32       | 0.009   |

**Cell Adhesion Proteins**

| Gene Symbol | Gene Product                                      | Fold Change | P-Value |
|-------------|--------------------------------------------------|-------------|---------|
| Cdh5        | Cadherin 5                                        | -5.00       | 0.043   |
| Itga9       | Integrin subunit alpha 9                         | -2.91       | 0.047   |
| Itga11      | Integrin subunit alpha 11                         | -13.28      | 0.034   |
| Pcdh7       | Protocadherin 7                                  | -2.71       | 0.015   |
| Pcdha1      | Protocadherin alpha 1                            | -1.44       | 0.042   |
| Pcdha8      | Protocadherin alpha 8                            | 2.26        | 0.002   |
| Selplg      | P-selectin glycoprotein ligand 1                  | -3.94       | 0.006   |

**Cytokines/Growth Factors**

| Gene Symbol | Gene Product                                      | Fold Change | P-Value |
|-------------|--------------------------------------------------|-------------|---------|
| Ccl6        | Chemokine (C-C motif) ligand 6                    | -8.76       | 0.005   |
| Gdf6        | Growth differentiation factor 6                   | -4.10       | 0.019   |
| Ifna14      | Interferon alpha 14                              | 1.27        | 0.043   |
| Igf1        | Insulin-like growth factor 1                      | -5.06       | 0.027   |
| Pdgfb       | Platelet-derived growth factor subunit B         | -2.59       | 0.011   |
| Pgf         | Placental growth factor                           | -4.96       | 0.037   |
| Tnfsf9      | Tumor necrosis factor ligand superfamily member 9| 2.97        | 0.048   |

**Enzymes**

| Gene Symbol | Gene Product                                      | Fold Change | P-Value |
|-------------|--------------------------------------------------|-------------|---------|
| Bmp1        | Bone morphogenetic protein 1                     | -2.36       | 0.016   |
| Casp3       | Caspase 3                                         | 2.06        | 0.040   |
| Cnd1        | Cyclin D1                                        | 2.20        | 0.043   |
| Gucy1b3     | Guanylate cyclase 1 soluble subunit beta          | -8.95       | 0.033   |
| Ikbkb       | Inhibitor of nuclear factor kappa-B kinase subunit beta | 1.34 | 0.001   |
| Lpl         | Lipoprotein lipase                               | -14.24      | 0.022   |
| Mmp23       | Matrix metalloproteinase 23                      | -6.61       | 0.049   |
| Pde1a       | Ca2+/calmodulin dependent phosphodiesterase 1A   | -4.73       | 0.028   |
| Pde2a       | Phosphodiesterase 2A                             | -1.91       | 0.048   |
| Prkg1       | cGMP-dependent protein kinase 1 (PKG)             | -9.09       | 0.034   |
| Ptgs1       | Prostaglandin-endoperoxide synthase 1 (COX-1)    | 2.22        | 0.027   |
| Sirt1       | Sirtuin 1                                        | -1.52       | 0.034   |
| Tnfaip3     | TNF alpha induced protein 3                      | 3.46        | <0.001  |

**Receptors**

| Gene Symbol | Gene Product                                      | Fold Change | P-Value |
|-------------|--------------------------------------------------|-------------|---------|
| Adra2a      | Adrenoceptor alpha 2A                             | -6.49       | 0.002   |
| Agtr1b      | Angiotensin II type 1b receptor                   | -9.88       | 0.043   |
| Avpr1a      | Arginine vasopressin receptor 1A                  | -6.62       | 0.010   |
| Cxcr4       | Chemokine (C-X-C motif) receptor 4                | -6.55       | 0.040   |
| Igf2r       | Insulin like growth factor 2 receptor             | -1.48       | 0.012   |
| Il3ra       | Interleukin 3 receptor subunit alpha              | -2.38       | 0.023   |
| Il20ra      | Interleukin 20 receptor alpha                     | -3.52       | 0.003   |
| Pdgfrb      | Platelet-derived growth factor receptor beta      | -2.89       | 0.016   |
| Pth1r       | Parathyroid hormone 1 receptor                    | -5.42       | 0.002   |

*Average fold gene expression change in c-Kit deficient smooth muscle cells compared to wild type cells.*
Table 2. Selected canonical pathways with differentially expressed genes in c-Kit deficient vs. wild type smooth muscle cells
| Pathway                  | Biological Function                          | P-Value | Z-Score | Predicted Status | Differentially Expressed Genes                                                                 |
|-------------------------|---------------------------------------------|---------|---------|------------------|-----------------------------------------------------------------------------------------------|
| PTEN signaling<sup>b</sup> | Proliferation, apoptosis, de-differentiation, cell migration, inflammation | <0.001  | 0.258   | Activation       | Akt2, Casp3, Rac1, Ccnd1, Igif2r, Rac3, Ddr1, She1, Ikbkb, Ipp5f, Foxo1, Bmp1r1a, Mag2I, Mag33, Pdgfrb |
| Death receptor signaling<sup>b</sup> | Apoptosis                                   | 0.003   | 1.265   | Activation       | Map2k4, Gas2, Rock1, Diabolo, Ikbkb, Casp3, Htra2, Tbk1, Parp1, Birc2                          |
| TNFR2 signaling<sup>b</sup> | Cell survival, inflammation                 | 0.005   | 1.000   | Activation       | Map2k4, Ikbkb, Tnfaip3, Tbk1, Birc2                                                           |
| Wnt/β-catenin signaling | Proliferation, cell survival, cell migration | 0.008   | 0.577   | Activation       | Sfrp4, Akt2, Crebbp, Csnnk1a1, Fzd9, Ccnd1, Rarg, Fzd8, Cdh5, Dkk3, Sox18, Pppr25e, Sfrp1, Wnt5b |
| IRF activation pathway<sup>b</sup> | Inflammation                               | 0.011   | 1.134   | Activation       | Map2k4, Ikbkb, Crebbp, Tbk1, Ifna14, Irf3, Atrf                                               |
| ERK/MAPK signaling      | Proliferation, cell migration, vasoconstriction | 0.028   | 1.069   | Activation       | Crebbp, Rac1, Pppr14a, Mknk2, Rac3, Nfatc1, Atf2, Pla2g4e, She1, Pla2g6, Prkar2b, Prkg2, PpS6ka1, Pppr25e |
| TNFR1 signaling<sup>b</sup> | Cell survival, inflammation                | 0.044   | 1.000   | Activation       | Map2k4, Ikbkb, Casp3, Tnfaip3, Birc2                                                          |
| Wnt/Ca<sup>2+</sup> pathway<sup>b</sup> | Proliferation, cell migration              | <0.001  | -1.000  | Inhibition       | Fzd8, Pcleb4, Crebbp, Nfatc2, Fzd9, Nfatc4, Wnt5b, Nfatc1, Atf2                               |
| AMPK signaling<sup>b</sup> | Cellular senescence, anti-inflammatory, differentiation, vasoconstriction | <0.001  | -0.535  | Inhibition       | Pbrm1, Akt2, Crebbp, Ccnd1, Sla2a4, Elav11, Atf2, Ak6, Prkar2b, Foxo1, Adra2a, Ppm1b, Sirt1, Prkg2, Ppm1a, Pppr25e, Ppat, Camkk2 |
| Apoptosis signaling<sup>b</sup> | Apoptosis                                   | <0.001  | -0.302  | Inhibition       | Map2k4, Gas2, Rock1, Diabolo, Ikbkb, Casp3, Htra2, Rps6ka1, Bcl2a1, Parp1, Birc2             |
| Phospholipase C signaling | Vasoconstriction, stress responses          | 0.001   | -0.378  | Inhibition       | Rala, Arhgefl2, Pld3, Fcgr2a, Arhgefl5, Crebbp, Rac1, Pppr14a, Nfatc4, Fcgr2b, Rhoh, Nfatc1, Atf2, Pla2g4e, Plch4, Itp3r, Fccer1g, Nfatc2 |
| Nitric oxide/GC signaling | Vasodilation                               | 0.005   | -0.302  | Inhibition       | Bdkrb2, Knga1, Pde2a, Akt2, Prkg1, Prkar2b, Itp3r, Prkg2, Pde1a, Gucy1b3, Pgf                |
| Integrin signaling      | Cell adhesion, cell migration, proliferation, apoptosis, stress responses, differentiation | 0.029   | -1.387  | Inhibition       | Map2k4, Rala, Rac1, Rac3, Rhoh, Pdgfb, Rock1, Arhgap5, She1, Itga11, Itga9, Actn4, Tspan6, Nedd9 |
| Adipogenesis pathway    | Lipid synthesis and storage                | <0.001  | N.D.    | Could not be predicted | Nr2f2, Sin3b, Fzd9, Nfatc4, Rbp1, Sla2a4, Fzd8, Cdk5, Foxo1, Bmp1r1a, Lpl, Sirt1, Cctb2, Clock, Fabp4, Rps6ka1, Stat5b |
| Fibroblast inflammatory pathway<sup>b</sup> | Proliferation, cell migration, differentiation, inflammation | 0.012   | N.D.    | Could not be predicted | Map2k4, Sfrp4, Akt2, Crebbp, Csnnk1a1, Rac1, Fzd9, Nfatc4, Ccnd1, Nfatc1, Pdgfb, Pgf, Atf2, Rock1, Ikbkb, Fzd8, Plcb4, Dkk3, Nfatc2, Shfip1, Wnt5b |
| Gaq signaling<sup>b</sup> | Proliferation, cell migration, vasoconstriction | 0.026   | 0.000   | Could not be predicted | Rock1, Ikbkb, Plcb4, Akt2, Pld3, Agtr1b, Itp3r, Nfatc2, Nfatc4, Avp1r1a, Rhoh, Nfatc1 |

<sup>a</sup> Z-score and predicted functional status in c-Kit deficient smooth muscle cells compared to wild type cells. The z-score measures how well the gene expression data matches the experimentally observed direction of pathway regulation in the literature. A positive z-score predicts activation, while a negative z-score indicates inhibition. N.D., could not be determined.

<sup>b</sup> NF-κB associated signaling pathway
Manuscript to be reviewed
Figure 1

Figure 1. Loss of c-Kit function accounts for significant gene expression differences between c-Kit deficient and wild type smooth muscle cells (SMC).

A) Venn diagram indicating the numbers of differentially upregulated genes in primary SMC isolated from c-Kit deficient (blue; Kit<sup>W/W<sup>-v</sup></sup>) and littermate control mice (red; Kit<sup>+/+</sup>) as determined by microarray analysis. The group of genes in the interception (black area) did not show statistically significant differences by <em>t</em>-test between the two strains (n=3 per group). B) Heat map of differentially expressed genes in primary SMC from c-Kit deficient and littermate control mice. C) Expression of NF-κB related genes in c-Kit deficient vs. control SMC as determined by real-time PCR. Values are shown as fold change over expression in Kit<sup>+/+</sup> cells; * p<0.05 and ** p<0.01 using a two-tailed <em>t</em>-test assuming unequal variance, n=3 per group.
Figure 2

Figure 2. Loss of c-Kit function in primary smooth muscle cells (SMC) is associated with increased NF-κB activity.

**A)** NF-κB transcriptional activity in c-Kit deficient (Kit^{W/W-}), control (Kit^{+/+}), and c-Kit rescued SMC (Kit^{R}) after 24-hour treatment with POVPC (50 µg/ml), as determined by dual-luciferase reporter assay. Transcriptional activity is represented as the mean ± standard deviation (SD) of the Firefly/Renilla luciferase ratio normalized with respect to the control group (Kit^{+/+}) (n=3 independent experiments). **B)** Phosphorylated (pS536) protein levels of the NF-κB p65 subunit in POVPC-treated c-Kit deficient, control, and c-Kit rescued SMC as determined by ELISA. Values are expressed as the mean ± SD of the p-p65/total p65 ratio normalized with respect to the control group (Kit^{+/+}) (n=3 independent experiments). **C)** Protein expression of the NF-κB related pro-inflammatory mediators MMP-2 and MCP-1 in POVPC-treated c-Kit deficient, control, and c-Kit rescued SMC as determined by Western blot. Molecular weight markers are shown on the right side of the gel. Protein expression is expressed as the mean ± SD of the MMP-2/β-actin and MCP-1/β-actin signal ratios normalized with respect to the control group (Kit^{+/+}) (n=3 per cell type). * p<0.05 and ** p<0.01 using a one-way ANOVA followed by a Newman-Keuls test.
Figure 3

Figure 3. c-Kit inhibits NF-κB activity in smooth muscle cells (SMC) through the actions of TAK1 and NLK.

**A)** Protein expression of the TAK1 and NLK regulatory proteins in c-Kit deficient (Kit<sup>W/W-v</sup>), control (Kit<sup>+/+</sup>), and c-Kit rescued SMC (Kit<sup>R</sup>) as determined by Western blot. Protein expression is expressed as the mean ± standard deviation (SD) of the TAK1/β-actin and NLK/β-actin signal ratios normalized with respect to the control group (Kit<sup>+/+</sup>) (n=3 per cell type).

**B-C)** Protein expression of TAK1 (**B**) and NLK (**C**) in Kit<sup>+/+</sup> cells transduced with lentivirus-encoded siRNAs of the corresponding targets or GFP control. Protein expression is expressed as the mean ± SD of the TAK1/β-actin and NLK/β-actin signal ratios normalized with respect to the siGFP-treated group (n=3 independent experiments).

**D)** NF-κB transcriptional activity in Kit<sup>+/+</sup> SMC transduced with lentivirus-encoded siRNAs complementary to TAK1, NLK, or GFP after 24-hour treatment with POVPC (50 µg/ml), as determined by dual-luciferase assay. Transcriptional activity is represented as the mean ± SD of the Firefly/Renilla luciferase ratio normalized with respect to the siGFP-treated group (n=3 independent experiments).

**E)** Phosphorylated (pS536) protein levels of NF-κB p65 in POVPC-treated Kit<sup>+/+</sup> SMC transduced with lentivirus-encoded siRNAs as determined by ELISA. Values are expressed as the mean ± SD of the p-p65/total p65 ratio normalized with respect to the siGFP-treated group (n=3 independent experiments).

**F)** Protein expression of the pro-inflammatory mediators MMP-2 and MCP-1 in POVPC-treated Kit<sup>+/+</sup> SMC transduced with lentivirus-encoded siRNAs as determined by Western blot. Protein expression is expressed as the mean ± SD of the MMP-2/β-actin and MCP-1/β-actin signal ratios normalized with respect to the siGFP-treated group (n=3 independent experiments). Molecular weight markers are shown on the right side of the gels. * p<0.05 and ** p<0.01 using a one-way ANOVA followed by a Newman-Keuls test.
Figure 4

Figure 4. c-Kit forms a molecular complex with the regulatory proteins TAK1, Src, and NLK in smooth muscle cells (SMC).

A) Diagram illustrating the proposed molecular complex between c-Kit, TAK1, Src, and NLK in SMC and their inhibitory function on NF-κB transcriptional activity. B-C) Co-immunoprecipitation experiments in control (Kit\(^{+/+}\)) and c-Kit deficient (Kit\(^{W/W-v}\)) SMC using anti-c-Kit (B) and anti-TAK1 antibodies (C) to pull down protein complexes. Molecular weight markers are shown on the right side of the gels, while antibodies used to detect eluted proteins are indicated on the left. IP, immunoprecipitation; IB, immunoblot.